Mondal, J., Zhang, J., Qing, F., Li, S., Kumar, D., Huse, J. T., & Giancotti, F. G. (2025). Brd7 loss reawakens dormant metastasis initiating cells in lung by forging an immunosuppressive niche. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-56347-2

Daly, A. F., Dunnington, L. A., Rodriguez-Buritica, D. F., Spiegel, E., Brancati, F., Mantovani, G., Rawal, V. M., Faucz, F. R., Hijazi, H., Caberg, J.-H., Nardone, A. M., Bengala, M., Fortugno, P., Del Sindaco, G., Ragonese, M., Gould, H., Cannavò, S., Pétrossians, P., Lania, A., … Franke, M. (2024). Chromatin conformation capture in the clinic: 4C-seq/HiC distinguishes pathogenic from neutral duplications at the GPR101 locus. Genome Medicine, 16(1). https://doi.org/10.1186/s13073-024-01378-5

Watanabe, J., Clutter, M. R., Gullette, M. J., Sasaki, T., Uchida, E., Kaur, S., Mo, Y., Abe, K., Ishi, Y., Takata, N., Natsumeda, M., Gadd, S., Zhang, Z., Becher, O. J., & Hashizume, R. (2024). BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma. Journal of Clinical Investigation, 134(13). https://doi.org/10.1172/jci174794

Salokivi, T., Parkkola, R., Rajendran, Y., Bharadwaj, T., Acharya, A., Leal, S. M., Järvelä, I., Arvio, M., & Schrauwen, I. (2023). A novel variant in CYFIP2 in a girl with severe disabilities and bilateral perisylvian polymicrogyria. American Journal of Medical Genetics Part A, 194(4). Portico. https://doi.org/10.1002/ajmg.a.63478

Xiao, M., Kondo, S., Nomura, M., Kato, S., Nishimura, K., Zang, W., Zhang, Y., Akashi, T., Viny, A., Shigehiro, T., Ikawa, T., Yamazaki, H., Fukumoto, M., Tanaka, A., Hayashi, Y., Koike, Y., Aoyama, Y., Ito, H., Nishikawa, H., … Inoue, D. (2023). BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-44081-6

Bosch, E., Popp, B., Güse, E., Skinner, C., van der Sluijs, P. J., Maystadt, I., Pinto, A. M., Renieri, A., Bruno, L. P., Granata, S., Marcelis, C., Baysal, Ö., Hartwich, D., Holthöfer, L., Isidor, B., Cogne, B., Wieczorek, D., Capra, V., Scala, M., … Vasileiou, G. (2023). Elucidating the clinical and molecular spectrum of SMARCC2-associated NDD in a cohort of 65 affected individuals. Genetics in Medicine, 25(11), 100950. https://doi.org/10.1016/j.gim.2023.100950

Patel, S., Mckean, M., Piperno-Neumann, S., Shoushtari, A. N., Hernandez-Aya, L., Orloff, M., Khan, S., Montazeri, K., Kapiteijn, E., Buchbinder, E., Agresta, S., Reilly, S., Patriquin, C. M., Hickman, D., Corrigan, D., Granlund, L., Hentemann, M., Piel, J., Martin, P., & Mehmi, I. (2023). 1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma. Annals of Oncology, 34, S677–S678. https://doi.org/10.1016/j.annonc.2023.09.2262

Li, S., Fu, J., Liu, G., Ma, H., Mapara, M., Marcireau, C., & Lentzsch, S. (2023). P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism. Clinical Lymphoma Myeloma and Leukemia, 23, S145–S146. https://doi.org/10.1016/s2152-2650(23)01818-9

Ozturk, D. G., Özkan, H., Akcan, U., & Korkmaz, G. (2023). 23P Synthetic lethality by targeting RHEB in ARID1A-mutated luminal breast cancer. ESMO Open, 8(1), 100989. https://doi.org/10.1016/j.esmoop.2023.100989

Iwamoto, F., Gondi, V., Butowski, N., Falchook, G., Williams, A., Peters, K. B., Evans, J., Lakhani, N., McKean, M., Symeonides, S., Ellingson, B., Rotolo, J., Capiaux, G., Wiegert, E., Michel, R., Kaesshaefer, S., & Bexon, A. (2022). CTNI-49. EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN Β (C/EBPΒ), IN RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology, 24(Supplement_7), vii83–vii83. https://doi.org/10.1093/neuonc/noac209.314

Coutinho, D. F., Mundi, P. S., Marks, L. J., Burke, C., Ortiz, M. V., Diolaiti, D., Bird, L., Vallance, K. L., Ibáñez, G., You, D., Long, M., Rosales, N., Grunn, A., Ndengu, A., Siddiquee, A., Gaviria, E. S., Rainey, A. R., Fazlollahi, L., Hosoi, H., … Dela Cruz, F. S. (2022). Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors. Med, 3(11), 774-791.e7. https://doi.org/10.1016/j.medj.2022.09.002

van der Sluijs, P. J., Joosten, M., Alby, C., Attié-Bitach, T., Gilmore, K., Dubourg, C., Fradin, M., Wang, T., Kurtz-Nelson, E. C., Ahlers, K. P., Arts, P., Barnett, C. P., Ashfaq, M., Baban, A., van den Born, M., Borrie, S., Busa, T., Byrne, A., Carriero, M., … Santen, G. W. E. (2022). Discovering a new part of the phenotypic spectrum of Coffin-Siris syndrome in a fetal cohort. Genetics in Medicine, 24(8), 1753–1760. https://doi.org/10.1016/j.gim.2022.04.010

Rubens, J. A., Erker, C., Lindsay, H., Ho, B., Li, B., Bouffet, E., Cohen, A., Eberhart, C., Ertl-Wagner, B., Mahajan, A., Zacharoulis, S., Huang, A., & Packer, R. (2022). Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board. Neuro-Oncology Advances, 4(1). https://doi.org/10.1093/noajnl/vdac092